|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01877 JUNSHI BIO
Nominal 
12.900 -1.540 (-10.665%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 786,056 | 17.374% | 1,502,550 | 1,453,493 | 4,024,841 | 1,594,897 |
| Cost of Sales | (210,801) | -26.935% | (667,290) | (526,282) | (1,258,187) | (372,531) |
| Gross Profit | 575,255 | 50.910% | 835,260 | 927,211 | 2,766,654 | 1,222,366 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 10,416 | -- | (23,484) | (47) | 342 | (255) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (28,225) | -12.632% | (60,484) | (71,032) | (48,463) | (3,805) | |
| Profit / (Loss) before Taxation | (684,894) | -41.752% | (2,489,887) | (2,675,202) | (592,648) | (1,669,461) | |
| Taxation | (3,551) | -- | (43,995) | 93,107 | (135,533) | 3,822 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 42,754 | -66.836% | 252,258 | 196,028 | 9,624 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (645,691) | -35.199% | (2,281,624) | (2,386,067) | (718,557) | (1,665,639) | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (61) | -99.849% | (70,420) | (31,648) | (9,146) | 9,113 |
| Depreciation & Amortisation | -- | -- | 303,220 | 263,907 | 262,559 | 151,362 |
| Directors' Emoluments | -- | -- | 55,345 | 68,691 | 102,780 | 96,137 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | -66.000 | -34.653% | -232.000 | -260.000 | -80.000 | -202.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (2.045) | (1.935) | (0.719) | (1.817) |
| NBV per share ($) | 6.591 | -- | 7.275 | 9.667 | 8.741 | 6.695 |
| Remarks: | Real time quote last updated: 13/11/2024 16:34 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -645,691,000 |
| %Change | -35.199% |
| EPS / (LPS) | RMB -0.660 |
| NBV Per Share (¥) | RMB 6.591 |